Navigation Links
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Date:2/4/2008

lop innovative improved products to meet the needs of interventional cardiologists and their patients," said Richard L. Klein, president of Medlogics. "Cardiovascular disease remains the nation's greatest killer, and we are committed to providing new technologies that can improve quality of life for these patients."

"Licensing our proprietary biopolymer stent coating technology to Medlogics with their best-in-class stent design allows CV Therapeutics to potentially generate revenues from future milestones and product sales and to continue focusing on maximizing the potential for Ranexa, regadenoson and our pipeline of pharmaceutical therapies," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

About Medlogics

Founded in August 2002, Medlogics is a California corporation based in Santa Rosa, California. Medlogics has vertically integrated drug eluting coating, stent and catheter research, de
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
(Date:9/2/2015)... ... , ... Temarry Recycling's new $100,000 waste to energy capital ... continue to contribute to the sustainability of our natural resources. , Waste to ... been operating at their Mexico facility, Recicladora Temarry, for the last 7 years. ...
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
(Date:9/1/2015)... N.J. , Sept. 1, 2015  ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... & Renshaw 17 th Annual Global Investment Conference ... place September 8-10, 2015 at The St. Regis Hotel ... James Sapirstein , Chief Executive Officer, ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... tissues normally discarded after surgical procedures could be a ... New research from BioMed Central,s open access Journal ... that human fallopian tubes are abundant in mesenchymal stem ... of cell types. It has previously been ...
... New research by a team of University of Toronto scientists ... variety of electronic devices including digital cameras. , Researchers ... digital camera that benefits from a phenomenon known as ... electrical current from a device that takes advantage of MEG. ...
... /PRNewswire-FirstCall/ - Following the announcement on April 30, 2009, ... Human Bionics Inc. ("Victhom", TSX: VHB) and Otto Bock ... of the transaction contemplated by the partnership agreement and ... the concurrent restructuring of its outstanding convertible debentures by ...
Cached Biology Technology:Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 2Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 3Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 4
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... has been identified by a team of scientists, including a ... treatments for those affected by the conditions brought on by ... and studying the gene in zebrafish embryos, and the team,s ... genetics of mice and people. "This work really ...
... U.S. Fish and Wildlife Service is excluding significant research ... even when the law governing the agency,s actions requires ... species need protection from extinction. A group of ... argue in the December issue of the journal ...
... NY) ─ Scientists at Albert Einstein College of ... finding about the method by which certain genes are ... that work with other genes to build protein structures ... are turned on randomly. The surprising discovery, described in ...
Cached Biology News:Scientists find gene linked to congenital heart defect 2Scientists find gene linked to congenital heart defect 3Scientists find gene linked to congenital heart defect 4Researchers: Include data about societal values in endangered species decisions 2Researchers: Include data about societal values in endangered species decisions 3Researchers: Include data about societal values in endangered species decisions 4Study of how genes activate yields surprising discovery 2Study of how genes activate yields surprising discovery 3
...
...
... Cultrex High Protein Concentration Basement Membrane ... use in in vivo applications where ... times, increased gel strength, and elevated ... has the advantage of lot-to-lot consistency ...
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
Biology Products: